<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008371</url>
  </required_header>
  <id_info>
    <org_study_id>19449</org_study_id>
    <nct_id>NCT01008371</nct_id>
  </id_info>
  <brief_title>Investigation of Neuro-hormonal Mechanisms of Hunger, Fullness and Obesity.</brief_title>
  <official_title>CCK-dysregulation: Mechanisms of Abnormal Food Regulation and Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Society of Nuclear Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine abnormal neuro-hormonal mechanisms that may impair
      the ability to feel full and which therefore, may lead to obesity.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No recruitment
  </why_stopped>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cholecystokinin serum level</measure>
    <time_frame>fasting- state, then at time points 30, 60 and 120 minutes post-meal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxytocin serum bioassay</measure>
    <time_frame>fasting-state, and then at time points of 30, 60 and 120 minutes post-meal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastric Emptying time</measure>
    <time_frame>calculated at time points 0.5, 1,2,3 and 4 hours post-meal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Perception of fullness using visual analog scales</measure>
    <time_frame>fasting-state, and then at time points of every half hour post-meal through completion of the scan</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mini International Neuro-psychiatric Interview (MINI)</measure>
    <time_frame>once within 30 days of the scan</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Obesity</condition>
  <condition>Gastric Emptying</condition>
  <condition>Anxiety</condition>
  <condition>Depression</condition>
  <condition>Panic Disorder</condition>
  <arm_group>
    <arm_group_label>Obese</arm_group_label>
    <description>Healthy obese subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-obese</arm_group_label>
    <description>Healthy non-obese subjects</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Community sample, patients of a weight management clinic and patients of Medical University
        of South Carolina
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 18 to 65 years of age.

          -  Obese Subjects with BMI &gt;40.

          -  Normal weight subjects with BMI = 18.5-24.9

        Exclusion Criteria:

          -  Age younger than 18 years and over 65 years of age.

          -  Current use of narcotics or morphine

          -  Previous gastric surgery

          -  Presence of the following disorders that are known to cause functional gastric stasis
             syndromes: Diabetes Mellitus, Hypothyroidism, Progressive Systemic Sclerosis, Systemic
             Lupus Erythematosus, Dermatomyositis, Familial Dysautonomia, Pernicious Anemia, Bulbar
             poliomyelitis, Amyloidosis, Gastric Ulcer, Post-vagotomy, Tumor-associated
             gastroparesis, Fabry disease, Myotonic Dystrophy, Post-operative ileus,
             Gastroenteritis.

          -  Presence of the following disorders that are known to cause delayed gastric emptying:
             peptic ulceration, recent surgery, pyloric hypertrophy, post-radiotherapy, ileus,
             anorexia nervosa, acute viral infections.

          -  Presence of the following disorders that are known to cause rapid gastric emptying:
             Pyloroplasty, Hemigastrectomy, Duodenal ulcer, Gastrinoma (Zollinger-Ellison
             syndrome), Hyperthyroidism

          -  Current use of Thyroxine as it is known to cause rapid gastric emptying

          -  Current or recent (within the last 2 weeks) use of anti-spasmodics or pro-kinetic
             medications.

          -  Current use of Hyperalimentation

          -  Presence of any metabolic disorder, such as: hyperglycemia, acidosis, hypokalemia,
             hypercalcemia, hepatic coma or myxedema.

          -  Current use of estrogen or progesterone

          -  Current use of the following drugs that are known to delay gastric emptying:
             Nifedipine, beta-adrenergic agonists, Isoproterenol, Theophylline, Sucralfate,
             anticholinergics, Levodopa, diazepam, tricyclic antidepressants, phenothiazine,
             Progesterone, oral contraceptives, alcohol, nicotine, opiates.

          -  Allergy to eggs or wheat.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly A Holes-Lewis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas W Uhde, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA. 2007 Nov 7;298(17):2028-37.</citation>
    <PMID>17986696</PMID>
  </reference>
  <reference>
    <citation>Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Am J Clin Nutr. 1998 Oct;68(4):899-917.</citation>
    <PMID>9771869</PMID>
  </reference>
  <reference>
    <citation>Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis. 2008 Feb;18(2):158-68. Epub 2007 Dec 3. Review.</citation>
    <PMID>18061414</PMID>
  </reference>
  <reference>
    <citation>Burton-Freeman B, Davis PA, Schneeman BO. Plasma cholecystokinin is associated with subjective measures of satiety in women. Am J Clin Nutr. 2002 Sep;76(3):659-67.</citation>
    <PMID>12198015</PMID>
  </reference>
  <reference>
    <citation>Konturek SJ, Konturek JW, Pawlik T, Brzozowski T. Brain-gut axis and its role in the control of food intake. J Physiol Pharmacol. 2004 Mar;55(1 Pt 2):137-54. Review.</citation>
    <PMID>15082874</PMID>
  </reference>
  <reference>
    <citation>Rehfeld JF. Accurate measurement of cholecystokinin in plasma. Clin Chem. 1998 May;44(5):991-1001.</citation>
    <PMID>9590372</PMID>
  </reference>
  <reference>
    <citation>Liddle RA, Morita ET, Conrad CK, Williams JA. Regulation of gastric emptying in humans by cholecystokinin. J Clin Invest. 1986 Mar;77(3):992-6.</citation>
    <PMID>3949984</PMID>
  </reference>
  <reference>
    <citation>McCann UD, Slate SO, Geraci M, Roscow-Terrill D, Uhde TW. A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy controls. Neuropsychopharmacology. 1997 Mar;16(3):229-37.</citation>
    <PMID>9138439</PMID>
  </reference>
  <reference>
    <citation>Zhang W, Gardell S, Zhang D, Xie JY, Agnes RS, Badghisi H, Hruby VJ, Rance N, Ossipov MH, Vanderah TW, Porreca F, Lai J. Neuropathic pain is maintained by brainstem neurons co-expressing opioid and cholecystokinin receptors. Brain. 2009 Mar;132(Pt 3):778-87. doi: 10.1093/brain/awn330. Epub 2008 Dec 2.</citation>
    <PMID>19050032</PMID>
  </reference>
  <reference>
    <citation>Moran TH, Dailey MJ. Minireview: Gut peptides: targets for antiobesity drug development? Endocrinology. 2009 Jun;150(6):2526-30. doi: 10.1210/en.2009-0003. Epub 2009 Apr 16. Review.</citation>
    <PMID>19372201</PMID>
  </reference>
  <reference>
    <citation>Konturek PC, Konturek JW, Cześnikiewicz-Guzik M, Brzozowski T, Sito E, Konturek SJ. Neuro-hormonal control of food intake: basic mechanisms and clinical implications. J Physiol Pharmacol. 2005 Dec;56 Suppl 6:5-25. Review.</citation>
    <PMID>16340035</PMID>
  </reference>
  <reference>
    <citation>Little TJ, Russo A, Meyer JH, Horowitz M, Smyth DR, Bellon M, Wishart JM, Jones KL, Feinle-Bisset C. Free fatty acids have more potent effects on gastric emptying, gut hormones, and appetite than triacylglycerides. Gastroenterology. 2007 Oct;133(4):1124-31. Epub 2007 Jul 3.</citation>
    <PMID>17919488</PMID>
  </reference>
  <reference>
    <citation>Monstein HJ, Grahn N, Truedsson M, Ohlsson B. Oxytocin and oxytocin-receptor mRNA expression in the human gastrointestinal tract: a polymerase chain reaction study. Regul Pept. 2004 Jun 15;119(1-2):39-44.</citation>
    <PMID>15093695</PMID>
  </reference>
  <reference>
    <citation>Ohlsson B, Forsling ML, Rehfeld JF, Sjölund K. Cholecystokinin stimulation leads to increased oxytocin secretion in women. Eur J Surg. 2002;168(2):114-8.</citation>
    <PMID>12113268</PMID>
  </reference>
  <reference>
    <citation>Borg J, Melander O, Johansson L, Uvnäs-Moberg K, Rehfeld JF, Ohlsson B. Gastroparesis is associated with oxytocin deficiency, oesophageal dysmotility with hyperCCKemia, and autonomic neuropathy with hypergastrinemia. BMC Gastroenterol. 2009 Feb 25;9:17. doi: 10.1186/1471-230X-9-17.</citation>
    <PMID>19243587</PMID>
  </reference>
  <reference>
    <citation>Runge CF. Economic consequences of the obese. Diabetes. 2007 Nov;56(11):2668-72. Epub 2007 Jun 29. Review.</citation>
    <PMID>17601989</PMID>
  </reference>
  <reference>
    <citation>Dall TM, Fulgoni VL 3rd, Zhang Y, Reimers KJ, Packard PT, Astwood JD. Potential health benefits and medical cost savings from calorie, sodium, and saturated fat reductions in the American diet. Am J Health Promot. 2009 Jul-Aug;23(6):412-22. doi: 10.4278/ajhp.080930-QUAN-226.</citation>
    <PMID>19601481</PMID>
  </reference>
  <reference>
    <citation>Zwirska-Korczala K, Konturek SJ, Sodowski M, Wylezol M, Kuka D, Sowa P, Adamczyk-Sowa M, Kukla M, Berdowska A, Rehfeld JF, Bielanski W, Brzozowski T. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. J Physiol Pharmacol. 2007 Mar;58 Suppl 1:13-35.</citation>
    <PMID>17443025</PMID>
  </reference>
  <reference>
    <citation>Abell TL, Camilleri M, Donohoe K, Hasler WL, Lin HC, Maurer AH, McCallum RW, Nowak T, Nusynowitz ML, Parkman HP, Shreve P, Szarka LA, Snape WJ Jr, Ziessman HA; American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J Nucl Med Technol. 2008 Mar;36(1):44-54. doi: 10.2967/jnmt.107.048116. Epub 2008 Feb 20.</citation>
    <PMID>18287197</PMID>
  </reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2009</study_first_submitted>
  <study_first_submitted_qc>November 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2009</study_first_posted>
  <last_update_submitted>May 21, 2013</last_update_submitted>
  <last_update_submitted_qc>May 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2013</last_update_posted>
  <responsible_party>
    <name_title>Kelly Holes-Lewis, M.D.</name_title>
    <organization>Medical University of South Carolina</organization>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Cholecystokinin</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Satiety</keyword>
  <keyword>Gastric emptying</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Depression</keyword>
  <keyword>Panic Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Panic Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

